Vol. 1 No. 11 (2021)
Reimbursement Recommendations

Tucatinib (Tukysa)

Published November 17, 2021

Key Messages

  • CADTH recommends that Tukysa should be reimbursed by public drug plans for the treatment of patients with advanced human epidermal growth factor receptor 2 (HER2)-positive breast cancer that cannot be removed by surgery or is metastatic, including patients with brain metastases, if certain conditions are met.
  • Tukysa should only be reimbursed if prescribed in combination with trastuzumab-capecitabine and the cost of Tukysa is reduced.
  • Tukysa should only be covered to treat patients who have been previously treated for HER2-positive breast cancer with trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1).